Cerebral amyloid angiopathy: one single entity?
- 11 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 38 (1) , 29-34
Abstract
Purpose of review: Cerebral amyloid angiopathy (CAA) is a common brain disorder among the elderly and individuals with Alzheimer's disease, where accumulation of amyloid-ß can lead to intracerebral hemorrhage and dementia. This review discusses recent developments in understanding the pathophysiology and phenotypes of CAA. Recent findings: CAA has a long preclinical phase starting decades before symptoms emerge. Its pathophysiology follows consecutive stages of amyloid-ß deposition, decreased vascular reactivity, nonhemorrhagic changes, and ultimately hemorrhages. Although impaired perivascular clearance is the leading hypothesis underlying CAA, several lines of evidence suggest that glymphatic dysfunction also plays a significant role in the disease process. Despite its common pathway, the disease course is variable. Some patients develop more microbleeds, while others develop larger hemorrhages, suggesting a differentiation in vascular remodeling. Some patients with CAA develop a symptomatic immune response, and inflammation could be an important contributor to vascular damage in CAA in general. Furthermore, the prion-like transmission of amyloid-β has been identified as a cause of iatrogenic CAA occurring decades after neurosurgical procedures involving cadaveric dura mater. Summary: Emerging evidence of sporadic, hereditary, inflammatory, and iatrogenic CAA suggests a complex interplay between brain clearance, inflammation and vascular remodeling leading to a diverse clinical phenotype.Keywords
This publication has 34 references indexed in Scilit:
- Cerebral amyloid angiopathy and the immune systemAlzheimer's & Dementia, 2024
- Non‐hemorrhagic imaging markers of cerebral amyloid angiopathy in memory clinic patientsAlzheimer's & Dementia, 2024
- Accelerating Alzheimer’s therapeutic development: The past and future of clinical trialsCell, 2023
- Progression of cerebral amyloid angiopathy: a pathophysiological frameworkThe Lancet Neurology, 2023
- Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid AngiopathyAnnals of Neurology, 2023
- Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysisAlzheimer's & Dementia, 2021
- Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related InflammationJAMA Neurology, 2020
- Different microvascular alterations underlie microbleeds and microinfarctsAnnals of Neurology, 2019
- Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related InflammationJAMA Neurology, 2016
- Variants at APOE influence risk of deep and lobar intracerebral hemorrhageAnnals of Neurology, 2010